News
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback